[Correlation between p53 immunohistochemistry and TP53 mutations in gliomas]

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Genetics

Context:

• Diffuse gliomas are primary brain tumors with varying TP53 mutation statuses.
• TP53 gene mutations are common in gliomas and impact prognosis and treatment.
• Accurate prediction of TP53 mutational status is crucial for glioma classification and management.

Purpose:

• To assess the diagnostic accuracy of p53 immunohistochemistry (IHC) in predicting TP53 gene mutations in diffuse gliomas.
• To determine an optimal threshold for p53 IHC positivity indicative of TP53 mutation.
• To evaluate p53 IHC as a potential surrogate for TP53 mutational analysis.

Summary:

• A retrospective study analyzed 242 diffuse gliomas using next-generation sequencing (NGS) and p53 IHC.
• p53 IHC positivity ≥20% strongly correlated with TP53 mutations (P<0.05), showing 75.6% sensitivity and 90.4% specificity.
• Completely negative p53 IHC results were associated with a higher TP53 mutation rate (6/17), warranting further genetic investigation.

Impact:

• p53 IHC can serve as a reliable, cost-effective alternative for TP53 mutation detection in gliomas when positivity is ≥20%.
• The study highlights the importance of considering TP53 sequencing for gliomas with completely negative p53 IHC results.
• Findings can refine glioma diagnosis and guide personalized treatment strategies based on TP53 status.